Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma
Guru Sonpavde, Benjamin L. Maughan, Bradley A. McGregor, Xiao X. Wei, Kerry L. Kilbridge, Richard J. Lee, Evan Y. Yu, Michael T. Schweizer, Bruce Montgomery, Heather H. Cheng, Andrew C. Hsieh, Rohit Jain, Jaspreet Singh Grewal, Cesar Pico-Navarro, Zarina Gafoor, Teresa Pico Perschy, Petros Grivas
Topics & Concepts
AtezolizumabMedicineModified vaccinia AnkaraCohortMetastatic Urothelial CarcinomaOncologyInternal medicineAdverse effectClinical endpointVacciniaImmunotherapySurgeryUrologyBladder cancerCancerClinical trialNivolumabRecombinant DNAUrothelial carcinomaBiologyBiochemistryGeneBladder and Urothelial Cancer TreatmentsImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers